From Wikipedia, the free encyclopedia
Sotagliflozin structure.svg
Clinical data
Trade namesZynquista
Routes of
By mouth
ATC code
Legal status
Legal status
  • EU: Rx-only [1]
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.231.837 Edit this at Wikidata
Chemical and physical data
Molar mass424.94 g·mol−1
3D model (JSmol)
  • CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl
  • InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1

Sotagliflozin, sold under the brand name Zynquista, is a drug approved in the European Union for people with type 1 diabetes.[2][1][3]

The most common side effect is genital infection in women.[1] Other common side effects include diabetic ketoacidosis, diarrhoea and genital infection in men.[1]

The US Food and Drug Administration (FDA) refused its approval for use in combination with insulin for the treatment of type 1 diabetes. It is developed by Lexicon Pharmaceuticals.[4][5][6]

Sotagliflozin is a combination sodium/glucose cotransporter 1 and 2 (SGLT1/2) inhibitor and is in the class of drugs known as gliflozins.


  1. ^ a b c d "Zynquista EPAR". European Medicines Agency (EMA). 27 February 2019. Retrieved 28 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. ^ Zynquista approved in EU for certain patients with type I diabetes
  3. ^ Chatzopoulos G, Tziomalos K (October 2020). "An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes". Expert Opinion on Pharmacotherapy. 21 (15): 1799–1803. doi:10.1080/14656566.2020.1793961. PMID 33108240. S2CID 225098786.
  4. ^ "Sotagliflozin as an Adjunct to Insulin for Type 1 Diabetes" (PDF). U.S. Food and Drug Administration (FDA).
  5. ^ "Sanofi: FDA advisory committee votes on Zynquista (sotagliflozin) as treatment for adults with type 1 diabetes" (Press release). Sanofi. 17 January 2019 – via GlobeNewswire.
  6. ^ "Sanofi: FDA advisory committee votes on Zynquista (sotagliflozin) as treatment for adults with type 1 diabetes". Sanofi (Press release). 18 January 2019. Retrieved 28 October 2020.

External links[edit]

  • "Sotagliflozin". Drug Information Portal. U.S. National Library of Medicine.